alpha-aminopyridine has been researched along with Neutropenia in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 9 (45.00) | 24.3611 |
| 2020's | 11 (55.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cai, Q; Song, W; Sun, X; Wang, L; Wang, Y; Xue, H; Zhang, H; Zhang, L; Zhang, M; Zou, L | 1 |
| Agterof, M; Brown-Glaberman, U; Campone, M; Chatterjee, S; De Laurentiis, M; Kudryavcev, I; Martín, M; Menon-Singh, L; Palácová, M; Wu, J; Zamagni, C | 1 |
| André, F; Arteaga, CL; Burris, HA; Cameron, DA; Campone, M; Chakravartty, A; Conte, P; Hart, L; Hortobagyi, GN; Janni, W; Le Gac, F; O'Shaughnessy, J; Petrakova, K; Serra, P; Sonke, GS; Stemmer, SM; Taran, T; Winer, EP; Yap, YS; Zarate, JP | 1 |
| Alvarez Lopez, IM; Anton Torres, A; Barnadas Molins, A; Bellet Ezquerra, M; Cantos Sanchez de Ibargüen, B; Ciruelos Gil, EM; de Casa, S; De la Cruz Merino, L; De la Haba-Rodriguez, J; de Toro Salas, R; Delgado Mingorance, JI; Diaz Fernandez, N; Galve Calvo, E; Gavila Gregori, J; Gimeno, A; Gonzalez-Santiago, S; Hernando Melia, C; Jiménez-Rodriguez, B; Martin, M; Martínez Jañez, N; Moreno Anton, F; Quiroga Garcia, V; Rodriguez Sanchez, CA; Salvador Bofill, J; Vicente Rubio, E; Vidal, M; Villanueva Vazquez, R | 1 |
| Hashishita, H; Kuwahara, S; Maeda, H; Takada, S; Takahashi, M; Tomioka, N; Umehara, K; Watanabe, K; Yamamoto, M | 1 |
| Chakraborty, A; Chakravartty, A; Darstein, C; Ho, YY; Ji, Y; Quinlan, M; Yang, S; Zarate, JP | 1 |
| Barbat, SH; Cornely, OA; Hodges, MR; Koehler, P; Kramer, WG; Limburg, E; Ostermann, H; Tawadrous, M; Teschner, D | 1 |
| Ameye, L; Awada, A; Azambuja, E; Brandão, M; Caparica, R; De Angelis, C; Desmedt, C; Di Cosimo, S; Eiger, D; Franzoi, MA; Kotecki, N; Lambertini, M; Piccart, M; Ponde, N | 1 |
| Alongi, F; Buglione, M; Costantino, G; Figlia, V; Guerini, AE; Maddalo, M; Magrini, SM; Pasinetti, N; Pedersini, R; Pedretti, S; Pegurri, L; Peretto, G; Salah, E; Simoncini, EL; Triggiani, L; Vassalli, L | 1 |
| André, VAM; Chen, SC; Enatsu, S; Goetz, MP; Hae Park, I; Hardebeck, MC; Im, SA; Inoue, K; Iwata, H; Masuda, N; Sakaguchi, S; Sledge, GW; Sohn, J; Toi, M; Turner, PK | 1 |
| Abuhelwa, AY; Badaoui, S; Hopkins, AM; McKinnon, RA; Modi, ND; Rowland, A; Shankaran, K; Shaw, E; Sorich, MJ | 1 |
| Carneiro, BA; Costa, R; Costa, RB; Giles, FJ; Gradishar, WJ; Helenowski, I; Kaplan, J; Peterson, J; Talamantes, SM | 1 |
| Bardia, A; Moy, B; Spring, LM; Zangardi, ML | 1 |
| Bardia, A; Blouin, GC; Spring, LM; Zangardi, ML | 1 |
| Niraula, S | 1 |
| D'Angelillo, RM; Dell'Aquila, E; Fiore, M; Greco, C; Ippolito, E; Petrianni, GM; Ramella, S; Silipigni, S; Tonini, G | 1 |
| Cersosimo, RJ | 1 |
| Dong, M; Fan, Y; Feng, J; Hong, X; Huang, H; Ke, X; Li, W; Lu, X; Ning, Z; Qi, J; Shen, Z; Shi, Y; Yu, L; Zhang, W; Zhao, X; Zhou, D; Zhu, J | 1 |
| Bai, O; Cai, Z; Chen, X; Ding, K; Dong, M; Gao, Y; He, H; Hou, M; Huang, H; Huang, X; Jia, B; Jin, J; Jin, Z; Li, W; Li, X; Li, Z; Liang, R; Liu, L; Liu, P; Liu, Q; Liu, T; Luo, J; Luo, Y; Qiu, L; Shen, J; Shi, Y; Song, Y; Su, H; Su, L; Sun, X; Sun, Z; Tan, H; Tang, X; Wang, H; Wang, J; Wang, S; Wang, X; Wu, G; Wu, J; Xu, J; Xu, W; Yang, H; Yang, J; Yi, P; Zeng, Q; Zhang, H; Zhang, L; Zhang, X; Zhang, Y; Zhang, Z; Zhao, W; Zhou, D; Zhou, J | 1 |
| Kobayashi, A; Okamoto, H | 1 |
4 review(s) available for alpha-aminopyridine and Neutropenia
| Article | Year |
|---|---|
Meta-analysis of selected toxicity endpoints of CDK4/6 inhibitors: Palbociclib and ribociclib.
Topics: Aminopyridines; Antineoplastic Agents; Breast Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Molecular Targeted Therapy; Neutropenia; Piperazines; Purines; Pyridines | 2017 |
Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations.
Topics: Aminopyridines; Benzimidazoles; Breast Neoplasms; Cell Cycle; Clinical Trials as Topic; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drug Interactions; Female; Humans; Molecular Targeted Therapy; Neutropenia; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines | 2017 |
Ribociclib for post-menopausal women with HR+/HER2- advanced or metastatic breast cancer.
Topics: Aminopyridines; Antineoplastic Agents; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Neoplasm Metastasis; Neutropenia; Postmenopause; Purines; Receptor, ErbB-2 | 2017 |
Cyclin-dependent kinase 4/6 inhibitors for the management of advanced or metastatic breast cancer in women.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Dose-Response Relationship, Drug; Fatigue; Female; Gastrointestinal Diseases; Humans; Molecular Targeted Therapy; Neoplasm Staging; Neutropenia; Piperazines; Progression-Free Survival; Protein Kinase Inhibitors; Purines; Pyridines; Randomized Controlled Trials as Topic | 2019 |
8 trial(s) available for alpha-aminopyridine and Neutropenia
| Article | Year |
|---|---|
Chidamide plus prednisone, etoposide, and thalidomide for untreated angioimmunoblastic T-cell lymphoma in a Chinese population: A multicenter phase II trial.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Etoposide; Humans; Lymphoma, T-Cell, Peripheral; Neutropenia; Prednisone; Thalidomide; Treatment Outcome | 2022 |
Ribociclib plus letrozole in male patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: subgroup analysis of the phase IIIb CompLEEment-1 trial.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms, Male; Humans; Letrozole; Male; Neutropenia; Purines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2022 |
Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer.
Topics: Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Intention to Treat Analysis; Letrozole; Middle Aged; Neoplasm Grading; Neutropenia; Purines; Receptor, ErbB-2; Receptors, Estrogen; Survival Analysis | 2022 |
Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2- advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Female; Humans; Letrozole; Middle Aged; Neutropenia; Protein Kinase Inhibitors; Receptor, ErbB-2 | 2022 |
Phase 1b safety and pharmacokinetics of intravenous and oral fosmanogepix in patients with acute myeloid leukaemia and neutropenia.
Topics: Adult; Aminopyridines; Antifungal Agents; Humans; Leukemia, Myeloid, Acute; Neutropenia | 2023 |
Clinical Implications of Body Mass Index in Metastatic Breast Cancer Patients Treated With Abemaciclib and Endocrine Therapy.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Benzimidazoles; Body Mass Index; Breast Neoplasms; Confidence Intervals; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Fulvestrant; Humans; Middle Aged; Neutropenia; Obesity; Odds Ratio; Overweight; Placebos; Progression-Free Survival; Thinness; Weight Loss | 2021 |
Abemaciclib in combination with endocrine therapy for East Asian patients with HR+, HER2- advanced breast cancer: MONARCH 2 & 3 trials.
Topics: Aminopyridines; Anastrozole; Aromatase Inhibitors; Benzimidazoles; Breast Neoplasms; Diarrhea; Double-Blind Method; Drug Therapy, Combination; Female; Fulvestrant; Humans; Letrozole; Neutropenia; Receptor, ErbB-2; Treatment Outcome | 2021 |
Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma.
Topics: Adult; Aged; Aminopyridines; Antineoplastic Agents; Benzamides; Disease-Free Survival; Enteropathy-Associated T-Cell Lymphoma; Female; Histone Deacetylase Inhibitors; Humans; Leukopenia; Lymphoma, Extranodal NK-T-Cell; Lymphoma, Large-Cell, Anaplastic; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell, Peripheral; Male; Middle Aged; Mycosis Fungoides; Neoplasm Recurrence, Local; Neutropenia; Skin Neoplasms; Thrombocytopenia; Treatment Outcome; Young Adult | 2015 |
8 other study(ies) available for alpha-aminopyridine and Neutropenia
| Article | Year |
|---|---|
Clinical Management of Potential Toxicity of Abemaciclib and Approaches to Ensure Treatment Continuation.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Female; Humans; Neutropenia; Treatment Outcome | 2023 |
Quantitative Assessment of Ribociclib Exposure-Response Relationship to Justify Dose Regimen in Patients with Advanced Breast Cancer.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Neutropenia; Purines; Receptor, ErbB-2 | 2023 |
A single-center retrospective safety analysis of cyclin-dependent kinase 4/6 inhibitors concurrent with radiation therapy in metastatic breast cancer patients.
Topics: Aminopyridines; Breast Neoplasms; Combined Modality Therapy; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Ileitis; Molecular Targeted Therapy; Neoplasm Metastasis; Neutropenia; Outcome Assessment, Health Care; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Radiotherapy; Retrospective Studies | 2020 |
Prediction of severe neutropenia and diarrhoea in breast cancer patients treated with abemaciclib.
Topics: Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Diarrhea; Female; Humans; Neutropenia; Receptor, ErbB-2 | 2021 |
Why upfront use of CDK inhibitors for the treatment of advanced breast cancer may be wasteful, and how we can increase their value.
Topics: Aminopyridines; Antineoplastic Agents, Hormonal; Benzimidazoles; Breast Neoplasms; Cost-Benefit Analysis; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drug Costs; Female; Humans; Neutropenia; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Receptors, Estrogen; Receptors, Progesterone | 2019 |
Concurrent radiotherapy with palbociclib or ribociclib for metastatic breast cancer patients: Preliminary assessment of toxicity.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Agents; Breast Neoplasms; Chemoradiotherapy; ErbB Receptors; Female; Humans; Middle Aged; Neutropenia; Piperazines; Protein Kinase Inhibitors; Purines; Pyridines; Radiation Dosage; Treatment Outcome | 2019 |
Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminopyridines; Anemia; Antineoplastic Combined Chemotherapy Protocols; Benzamides; China; Disease-Free Survival; Fatigue; Female; Histone Deacetylase Inhibitors; Humans; Lymphoma, T-Cell, Peripheral; Male; Middle Aged; Neutropenia; Recurrence; Remission Induction; Salvage Therapy; Thrombocytopenia; Young Adult | 2017 |
Spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis.
Topics: Aminopyridines; Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Intracellular Signaling Peptides and Proteins; Lymphocyte Specific Protein Tyrosine Kinase p56(lck); Morpholines; Neutropenia; Oxazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; src-Family Kinases; Syk Kinase | 2011 |